Memantine is the first in a novel class of Alzheimer's disease medications acting on the glutamatergic system. It is also being tested for use as a cognitive enhancer in a variety of other conditions.
Read more...
| Reasons taken | # of patients | Major | Moderate | Slight | None | Can’t tell | # of patients evaluated by |
|---|---|---|---|---|---|---|---|
| Slow my ALS progress | 15 |
|
1 | ||||
| Other | 12 |
|
2 | ||||
| Brain fog | 5 |
|
|
2 | |||
| Memory problems | 5 |
|
1 | ||||
| Cognition | 3 |
|
1 | ||||
| Emotional lability | 2 | 0 |
See all 57 patients currently taking Memantine
Mouse over the table for more information
| Reason | # Patients | Percentage of patients | |
|---|---|---|---|
|
Did not seem to work
|
8 | 73% |
|
|
Side effects too severe
|
2 | 18% |
|
|
Expense
|
1 | 9% |
|
|
Personal research
|
1 | 9% |
|
|
Other
|
1 | 9% |
|
Report created on November 21, 2009.